Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00101946 | Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease | PHASE2 | COMPLETED | 17 | — | — | Oct 1, 2004 | Jul 1, 2006 | Apr 13, 2015 | 19 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| 683699 | DRUG | - |
Inclusion criteria: * Diagnosed with CD and reconfirmed in previous 2 years by a radiologic or endoscopic assessment including histology. * CDAI (Crohn's Disease Activity Index) score of 220-450 after 1 week of screening. * CRP (C-Reactive Protein) level of \>4mg at screening. Exclusion criteria: ...